The influenza virus circulates continue indefinitely, causing regional epidemics and outbreaks that have resulted in thousands of deaths. For instance, according to data from the Centers for Disease Control and Prevention (CDC), more than 13 million flu cases have been recorded in the 2019-20 timeframe. The changing nature of the virus necessitates an annual change in the vaccine strain to match the influenza virus strain around the world. During the forecasted period, the increasing prevalence of influenza epidemics and seasonal outbreaks is expected to boost product sales.
Global Influenza Vaccine Market size was valued at USD 7.9 billion in 2023 and is poised to grow from USD 8.44 billion in 2024 to USD 14.28 billion by 2032, growing at a CAGR of 6.8% during the forecast period (2025-2032).
In the current market scenario, there are numerous licensed seasonal influenza vaccines recommended by the World Health Organization (WHO), Centers for Disease Control and Prevention (CDC), and other governmental organizations to help fight the disease. Governments have focused on encouraging people to get vaccinated as soon as possible to provide the best possible protection during flu season. Furthermore, pharmaceutical companies are constantly confronted with new challenges in developing a suitable vaccine against a specific strain. As a result, rising demand for effective flu vaccines is expected to drive the Influenza Vaccine Market market.
Get a Free Sample PDF of the Report – https://www.skyquestt.com/sample-request/Influenza-vaccine-market
Influenza Vaccine Market – Regional Analysis:
In 2021, North America dominated the influenza vaccine market and is anticipated to maintain its dominance throughout the forecast period. Rapid product launches, combined with technologically advanced vaccine manufacturing systems across the region, are expected to drive market growth in the region. Furthermore, rising influenza prevalence and high vaccine sales are expected to fuel market growth in North America.
In the coming years, Asia-Pacific is expected to grow at an exponential rate. Because of the region’s growing population in countries such as China and India, the demand for effective vaccines, which leads to higher sales, is expected to drive market growth. Furthermore, a proactive government initiative in the supply of flu vaccines across the region, combined with improved influenza control strategies, is expected to drive influenza market growth across the region. For example, in September 2020, Japan’s health ministry has begun preparing 31.2 million flu vaccines, 7% more than the previous year, in order to immunize its population against influenza.
Detailed Segmentation and Classification of the report (Market Size and Forecast – 2032, Y-o-Y growth rate, and CAGR):
The Influenza Vaccine Market can be segmented based on several factors, including product type, application, end-user, and distribution channel.
Global Influenza Vaccine Market is segmented by Type, Indication, Technology, Route of Administration, Age Group, Distribution Channel and region.
Based on Type, the market is segmented into Inactivated and Live Attenuated.
Based on Indication, the market is segmented into Quadrivalent and Trivalent.
Based on Technology, the market is segmented into Egg-based and Cell-based.
Based on Route of Administration, the market is segmented into Injection and Nasal Spray.
Based on Age Group, the market is segmented into Pediatric and Adult.
Based on Distribution Channel, the market is segmented into Hospital & Pharmacies, Government & Institutional Supply and Other.
Based on region, the market is segmented into North America, Europe, Asia Pacific, Latin America and Middle East & Africa.
Top Market Players in Influenza Vaccine Market are:
Sanofi Pasteur (France)
GlaxoSmithKline plc (GSK) (United Kingdom)
Seqirus (a CSL Limited Company) (Australia)
Pfizer Inc. (United States)
AstraZeneca PLC (United Kingdom)
Novavax, Inc. (United States)
Bharat Biotech (India)
Johnson & Johnson (United States)
MedImmune, LLC (AstraZeneca) (United States)
FluGen (United States)
Emergent BioSolutions (United States)
Sinovac Biotech Ltd. (China)
Bio Farma (Indonesia)
Serum Institute of India Pvt. Ltd. (India)
Abbott Biologicals B.V. (Netherlands)
Adimmune Corporation (Taiwan)
BIKEN Co., Ltd. (Japan)
Changchun BCHT Biotechnology Co. (China)
Recent Developments in Influenza Vaccine Market:
In June 2022, Sanofi restructured its immuno-oncology collaboration with Regeneron Pharmaceuticals, Inc. Regeneron will have worldwide exclusive licensing rights to Libtayo under the modified and restated license and partnership agreement.
In May 2022, GSK plc announced that it has entered into a final agreement to acquire Affinivax, Inc. (Affinivax), a clinical-stage biopharmaceutical business located in Cambridge, Boston, Massachusetts, for a $2.1 billion upfront payment and up to $1.2 billion in possible development milestones.
In May 2021, During the pandemic, Australia launched a national flu vaccination programme to reduce the population’s infection rate. As a result, seasonal vaccines are now available in Australia through community pharmacies and general practitioners.
In March 2021, Sanofi announced USD 736.9 million investment in its Canadian vaccine facility to increase supply of influenza vaccines in Canada, the United States, and Europe. With the goal of increasing supply in these countries, this facility will provide additional antigen and filling capacity for Sanofi’s Fluzone High-Dose Quadrivalent influenza vaccine.
You may Also Like
https://www.linkedin.com/pulse/digital-health-market-transforming-healthcare-ai-wearable-trivedi-bvxac/ – Digital Health Market
https://vinitsawant.hatenablog.com/entry/2025/04/29/135724 – Polymethyl Methacrylate Market
Forward-Looking Insights
The Influenza Vaccine Market is set to experience sustained growth, fueled by technological advancements, broader global market access, and rising industry demand. With the industry addressing emerging challenges and capitalizing on new opportunities, it is expected to drive innovation and play a pivotal role in advancing global health and economic progress.
About Company:
SkyQuest is an IP focused Research and Investment Bank and Accelerator of Technology and assets. We provide access to technologies, markets and finance across sectors viz. Life Sciences, CleanTech, AgriTech, NanoTech and Information & Communication Technology.
We work closely with innovators, inventors, innovation seekers, entrepreneurs, companies and investors alike in leveraging external sources of R&D. Moreover, we help them in optimizing the economic potential of their intellectual assets. Our experiences with innovation management and commercialization have expanded our reach across North America, Europe, ASEAN and Asia Pacific.
Contact Details:
SkyQuest Technology Group
USA (+1) 351-333-4748
Email: [email protected]
